32. (C) Studies in children with idiopathic pulmonary arterial hypertension (
IPAH) and hereditary
PAH (
HPAH) have shown that the survival of those treated prior to the advent of targeted therapies (1950s to 1990s) was 66%, 52%, and 35% for 1, 3, and 5 years, respectively. Studies utilizing targeted therapies such as sildenafil, bosentan, and
IV prostacyclin have shown considerable improvement in morbidity and mortality associated with
PAH. The 1-, 3-, and 5-year survival rates improved to 94%, 88%, and 81% in a number of studies. The most likely presenting symptoms in children with
PAH are dyspnea, fatigue, syncope, or near-syncope. Children are unlikely to present with right heart failure as an initial finding as they are often quite active. Dyspnea on exertion is an early symptom. Children or adults who develop
PAH as a result of unrepaired congenital heart disease such as a large
VSD typically have a lower mortality than those with
IPAH or
HPAH as it takes more time for secondary
PAH to develop.